Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines regulation

Medicines regulators set out priorities for next five years

Medicines regulators across Europe have set out their priorities for the next five years in a proposed strategy now out for consultation.

For the first time, a coordinated plan has been produced jointly by the European Medicines Agency and the individual heads of national agencies that regulate medicines in each member state of the European Economic Area.

Priorities include managing the threat of antimicrobial resistance and the contribution that medicines regulators can make to the availability of drugs for conditions such as dementia. Drugs for children and older people and for patients with rare conditions is another focus for medicines regulators until 2020.

Preventing shortages in the medicines supply chain – which the strategy acknowledges has become increasingly complicated – and keeping it free of counterfeit products is also important. In the coming five years, there is likely to be a need for more cross-border collaboration in times of supply disruptions, the plan, entitled ‘EU Medicines Agency Network Strategy to 2020’, points out.

“Greater focus will be given to the increasing threat posed by the illegal supply chain of medicines that operates mostly through websites located in third countries,” it says.

Increased partnership working to tackle unexpected public health emergencies, similar to the action taken in the recent Ebola epidemic, will also be a priority. Responding to public health emergencies could include facilitating the introduction of new treatments or new preventive measures.

The document is out for public consultation until 30 June 2015.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068280

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.